Zobrazeno 1 - 10
of 105
pro vyhledávání: '"G. Luschin-Ebengreuth"'
Autor:
Päivi Heikkilä, András Vörös, Barbara Gazić, Róbert Maráz, Tuomo J. Meretoja, Gábor Cserni, Gábor Boross, Tibor Takács, G. Luschin-Ebengreuth, Riccardo A. Audisio, György Lázár, Peter Regitnig, Andraz Perhavec, Janez Zgajnar, Marjut Leidenius
Publikováno v:
Surgical Oncology. 21:59-65
Sentinel lymph node (SN) biopsy offers the possibility of selective axillary treatment for breast cancer patients, but there are only limited means for the selective treatment of SN-positive patients. Eight predictive models assessing the risk of non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec382c9df29975314027a82035c0562
https://doi.org/10.1016/j.suronc.2011.12.001
https://doi.org/10.1016/j.suronc.2011.12.001
Autor:
Richard Greil, Hellmut Samonigg, Susanne Taucher, Lidija Filipcic, Günther G. Steger, Florian Fitzal, Sabine Pöstlberger, Paul Sevelda, Brigitte Mlineritsch, Christoph Tausch, G. Luschin-Ebengreuth, Michael Stierer, Herbert Stöger, Karin Haider, Raimund Jakesz, Christian F. Singer, Rupert Bartsch, Margaretha Rudas, Werner Kwasny, Michael Gnant, Peter Dubsky
Publikováno v:
Journal of Clinical Oncology. 30:722-728
Purpose Anastrozole (ANA) alone delivers significant disease-free survival benefits over tamoxifen (TAM) monotherapy in postmenopausal women with early estrogen receptor–positive breast cancer. The ABCSG-8 (Austrian Breast and Colorectal Cancer Stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38e085539e8a869baa8b4fc7c146ff21
https://doi.org/10.1200/jco.2011.36.8993
https://doi.org/10.1200/jco.2011.36.8993
Autor:
G Seitz, O. Tsybrovskyy, P Regitnig, A Bader, G. Luschin-Ebengreuth, Farid Moinfar, Sebastian Mannweiler, G Pristauz-Telsnigg, Manfred Ratschek, Vesna Bjelic-Radisic
Publikováno v:
Cancer Research. 71:P5-11
Background: Several studies have shown that MammaPrint's gene signatures allow prognostic stratification of breast cancers that is superior to the currently used clinico-pathological risk factors. MammaPrint has also been reported to predict chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fab179bdd57f4dd2d0c4585e31ecae88
https://doi.org/10.1158/0008-5472.sabcs11-p5-11-02
https://doi.org/10.1158/0008-5472.sabcs11-p5-11-02
Autor:
M. Gnant, Günther G. Steger, Christian F. Singer, Raimund Jakesz, Richard Greil, D Heck, Holger Eidtmann, G. Luschin-Ebengreuth, Brigitte Mlineritsch, Herbert Stoeger
Publikováno v:
Cancer Research. 70:P5-11
Background: ABCSG-12 examined the efficacy of ovarian suppression using goserelin combined with tamoxifen (TAM) or anastrozole (ANA) ± zoledronic acid (ZOL) in premenopausal patients with endocrine-responsive early breast cancer. Results at 48 month
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::deb461cfd5f880da418916118e985eed
https://doi.org/10.1158/0008-5472.sabcs10-p5-11-02
https://doi.org/10.1158/0008-5472.sabcs10-p5-11-02
Autor:
Friedrich Hofbauer, Michael Stierer, G. Luschin-Ebengreuth, Karin S. Kapp, Leonore Handl-Zeller, Susanne Taucher, G. Reiner, Michael Gnant, Christoph Tausch, Felix Sedlmayer, Karin Haider, B. Pakisch, Sabine Pöstlberger, Raimund Jakesz, Richard Pötter, Andrea Rottenfusser, W. Draxler, Werner Kwasny, Marianne Schmid, Josef Hammer
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 68:334-340
In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial.Between January 1996 and June 2004, the Austrian Breast and Colorectal Cancer Study Gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90fc3312af08b4085440508bb087e216
https://doi.org/10.1016/j.ijrobp.2006.12.045
https://doi.org/10.1016/j.ijrobp.2006.12.045
Autor:
Martina Mittlboeck, Marianne Schmid, Stephan Grampp, G. Luschin-Ebengreuth, Christian Menzel, Brigitte Mlineritsch, Hubert Hausmaninger, Michael Gnant, Raimund Jakesz, Arik Galid, Jutta Claudia Piswanger-Soelkner, Helmut Kaessmann
Publikováno v:
Journal of Clinical Oncology. 25:820-828
Purpose Adjuvant therapy for breast cancer can be associated with decreased bone mineral density (BMD) that may lead to skeletal morbidity. This study examined whether zoledronic acid can prevent bone loss associated with adjuvant endocrine therapy i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e10e79f10868165ce9ae1f4f4fa492ec
https://doi.org/10.1200/jco.2005.02.7102
https://doi.org/10.1200/jco.2005.02.7102
Autor:
Oleksiy Tsybrovskyy, G. Luschin-Ebengreuth, Renate Moser, Sigurd Lax, Peter Regitnig, Helmtraud Papadi, Ferdinand Ploner, Michael Thalhammer
Publikováno v:
The Journal of Pathology. 198:190-197
Local recurrence is a serious complication of breast carcinoma that reduces quality of life and influences prognosis. The aim of this study was to determine whether local recurrences of breast carcinoma are genetically related to the primary tumours.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b1ef72b0d979dc21870f8caec60d83
https://doi.org/10.1002/path.1193
https://doi.org/10.1002/path.1193
Autor:
E. Barranger, Zuhair Saidan, Vania Vezzosi, Rana Nadeem, Janez Zgajnar, Rita Bori, Tuomo J. Meretoja, Peter Regitnig, Maria Pia Foschini, Shigeru Imoto, Päivi Heikkilä, Tibor Takács, György Lázár, Tove Filtenborg Tvedskov, Andraz Perhavec, Marjut Leidenius, R. Lousquy, Barbara Gazić, Simonetta Bianchi, G. Luschin-Ebengreuth, Isabella Castellano, Riccardo A. Audisio, Gábor Cserni, M.-B. Jensen, Riccardo Arisio, István Sejben, Hiroshi Kamma, Bence Kővári, Anna Sapino
Publikováno v:
Breast cancer research and treatment. 138(3)
Recently, many centers have omitted routine axillary lymph node dissection (ALND) after metastatic sentinel node biopsy in breast cancer due to a growing body of literature. However, existing guidelines of adjuvant treatment planning are strongly bas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e20084921d9bb797e59026babb114390
https://pubmed.ncbi.nlm.nih.gov/23558360
https://pubmed.ncbi.nlm.nih.gov/23558360
Autor:
E. Barranger, György Lázár, Tove Flitenborg Tvedskov, Simonetta Bianchi, G. Luschin-Ebengreuth, Gábor Boross, Janez Žgajnar, Peter Regitnig, Rana Nadeem, András Vörös, Tibor Takács, Andraz Perhavec, Gábor Cserni, Vania Vezzosi, Hiroshi Kamma, Maria Pia Foschini, Maj Brit Jensen, Riccardo Arisio, Niels Thorndahl Kroman, Shigeru Imoto, Barbara Gazić, Zuhair Saidan, Päivi Heikkilä, R. Lousquy, Tuomo J. Meretoja, István Sejben, Anna Sapino, Riccardo A. Audisio, Isabella Castellano, Marjut Leidenius
Publikováno v:
Journal of the National Cancer Institute. 104(24)
Background Axillary treatment of breast cancer patients is undergoing a paradigm shift, as completion axillary lymph node dissections (ALNDs) are being questioned in the treatment of patients with tumor-positive sentinel nodes. This study aims to dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::983955320ab700007d3f732402777289
https://pubmed.ncbi.nlm.nih.gov/23985140
https://pubmed.ncbi.nlm.nih.gov/23985140
Autor:
Marjut Leidenius, András Vörös, Riccardo A. Audisio, Tuomo J. Meretoja, Janez Zgajnar, Päivi Heikkilä, György Lázár, G. Luschin-Ebengreuth, Barbara Gazić, Rita Bori, Tibor Takács, Gábor Cserni, Róbert Maráz, Peter Regitnig, Andraz Perhavec
Publikováno v:
Pathology oncology research : POR. 19(1)
Although axillary lymph node dissection (ALND) has been the standard intervention in breast cancer patients with sentinel lymph node (SLN) metastasis, only a small proportion of patients benefit from this operation, because most do not harbor additio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed67037a012686a9d8fd5d107360f23
https://pubmed.ncbi.nlm.nih.gov/22798061
https://pubmed.ncbi.nlm.nih.gov/22798061